Xenetic Biosciences, Inc. XBIO
2.37
(0.10)
(4.05%)
as of 25 Sep
- Market cap
- $5.8M
- P/E
- 0.0×
Follow XBIO
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| ROE |
+8 more TTM periods Free account |
(57.44%) | (40.01%) | (37.02%) | (47.05%) |
| ROA | (48.13%) | (35.12%) | (32.61%) | (40.17%) | |
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% | |
| Return on Tangible Assets | (79.78%) | (37.85%) | (33.66%) | (42.98%) | |
| Average Days of Receivables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow per Share | (1.76) | (1.34) | (0.79) | (1.01) | |
| Free Cash Flow | (2.72) | (2.29) | (1.82) | (2.31) | |
| Piotroski F-Score | 2.00 | 4.00 | 3.00 | 4.00 | |
| Other line items | |||||
| Cash ROIC | (33.65%) | (14.97%) | (12.74%) | (18.44%) | |
| Accounts Receivable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 116.63% | 102.99% | 89.27% | 84.13% | |
| Selling, General and Administrative Expense of Revenue | 99.17% | 92.24% | 85.78% | 96.88% | |
| Share Based Compensation of Revenue | 2.65% | 2.18% | 1.78% | 2.86% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 0.86 | 0.85 | 0.82 | 0.93 | |
| Revenue per Share | 1.85 | 1.75 | 1.39 | 1.42 | |
| Operating CF per Share | (1.76) | (1.34) | (0.79) | (1.01) | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | (110.40%) | (90.07%) | (70.03%) | (75.90%) |
Columns are period end dates